Clinical trials
Observational Rare Diseases trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 42 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 17 |
| University Hospital Tuebingen | 3 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Centre Hospitalier Universitaire de Liege | 1 |
| Cystinosis Research Foundation | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| Fairview University Medical Center | 1 |
| Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia | 1 |
| IRCCS Eugenio Medea | 1 |
| IRCCS Ospedale San Raffaele | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rare Diseases | 42 |
| Genetic Diseases, Inborn | 8 |
| Endocrine System Diseases | 5 |
| Mental Disorders | 5 |
| Neurologic Manifestations | 5 |
| Respiratory Tract Diseases | 4 |
| Connective Tissue Diseases | 3 |
| Abnormalities, Multiple | 2 |
| Arthritis | 2 |
| Brain Injuries | 2 |
Trials
Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.